ATOS Atossa Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: ATOS
Price (delayed)
$0.8275
Market cap
$106.89M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.23
Enterprise value
$48.92M
Relative Growth:
Rel. Growth:
3
Relative Strength:
Rel. Strength:
31
Relative Valuation:
Rel. Valuation:
N/A
Relative Profitability:
Rel. Profitability:
5
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and
Highlights
The quick ratio has declined by 39% year-on-year and by 29% since the previous quarter
The company's equity fell by 28% YoY and by 12% QoQ
Key stats
What are the main financial stats of ATOS
Market
Valuations
Earnings
Shares outstanding
129.17M
Market cap
$106.89M
Enterprise value
$48.92M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.85
Price to sales (P/S)
N/A
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$29.99M
Net income
-$28.72M
EBIT
-$28.72M
EBITDA
-$28.7M
Free cash flow
-$25.04M
Per share
Balance sheet
Liquidity
EPS
-$0.23
EPS diluted
-$0.23
Free cash flow per share
-$0.19
Book value per share
$0.45
Revenue per share
$0
TBVPS
$0.5
Total assets
$64.52M
Total liabilities
$6.82M
Debt
$0
Equity
$57.7M
Working capital
$55.7M
Debt to equity
0
Current ratio
9.17
Quick ratio
8.5
Net debt/EBITDA
2.02
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-39.5%
Return on equity
-42.8%
Return on invested capital
N/A
Return on capital employed
-49.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATOS stock price
How has the Atossa Therapeutics stock price performed over time
Intraday
-2.43%
1 week
-5.63%
1 month
-18.07%
1 year
-40.89%
YTD
-12.35%
QTD
-4.56%
Financial performance
How have Atossa Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$29.99M
Net income
-$28.72M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 11% YoY and by 9% from the previous quarter
The operating income fell by 7% QoQ
Price vs fundamentals
How does ATOS's price correlate with its fundamentals
Growth
What is Atossa Therapeutics's growth rate over time
Valuation
What is Atossa Therapeutics stock price valuation
P/E
N/A
P/B
1.85
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 10% QoQ and by 10% YoY
The company's equity fell by 28% YoY and by 12% QoQ
ATOS's P/B is 2.8% above its 5-year quarterly average of 1.8 but 2.6% below its last 4 quarters average of 1.9
Efficiency
How efficient is Atossa Therapeutics business performance
The return on equity has declined by 47% year-on-year and by 18% since the previous quarter
The ROA has decreased by 43% YoY and by 17% from the previous quarter
Dividends
What is ATOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATOS.
Financial health
How did Atossa Therapeutics financials performed over time
The quick ratio has declined by 39% year-on-year and by 29% since the previous quarter
Atossa Therapeutics's current ratio has decreased by 36% YoY and by 28% from the previous quarter
ATOS's debt is 100% smaller than its equity
The company's equity fell by 28% YoY and by 12% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.